Pulmatrix (PULM) Stock Price, News & Analysis

Company Overview

Pulmatrix, Inc. is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for respiratory and other diseases. The company’s research is based on its iSPERSE dry-powder delivery technology, which is designed to enable efficient administration of pharmaceutical compounds directly to the lungs.

Pulmatrix’s pipeline has included PUR1900, an inhaled formulation of itraconazole being developed for respiratory fungal infections, including allergic bronchopulmonary aspergillosis. The company has also advanced PUR3100, an inhaled formulation of dihydroergotamine intended for the potential acute treatment of migraine. Development programs and indications may change as clinical and regulatory activities progress.

Based in Lexington, Massachusetts, Pulmatrix has historically concentrated on pharmaceutical development rather than commercial product sales. Its operations have primarily involved research, clinical testing and the potential partnering or licensing of inhaled medicines for patients in the United States and other international markets.

Key Stats

• Today's Range: $1.25 to $1.30
• 50-Day Range: $1.28 to $1.70
• 52-Week Range: $1.06 to $4.98
• Volume: 5,854 shs
• Average Volume: 39,103 shs
• Market Capitalization: $4.71 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Pulmatrix Stock Analysis - MarketRank™

Pulmatrix scored higher than 24% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Pulmatrix has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Pulmatrix has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Pulmatrix is -1.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Pulmatrix is -1.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Pulmatrix has a P/B Ratio of 0.53. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.09% of the float of Pulmatrix has been sold short.

Short Interest Ratio / Days to Cover

Pulmatrix has a short interest ratio ("days to cover") of 1.32, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Pulmatrix has recently decreased by 8.50%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Pulmatrix does not currently pay a dividend.

Dividend Growth

Pulmatrix does not have a long track record of dividend growth.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.91

News Sentiment

Pulmatrix has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Pulmatrix this week, compared to 1 article on an average week.

MarketBeat Follows

1 people have added Pulmatrix to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Pulmatrix insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.62% of the stock of Pulmatrix is held by insiders.

Percentage Held by Institutions

11.84% of the stock of Pulmatrix is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 11/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:PULM
• CIK: 1574235
• Web: www.pulmatrix.com
• Phone: (781) 357-2333
• Fax: 707-525-9906
• Employees: 2
• Year Founded: 2003

Profitability

• EPS (Trailing Twelve Months): ($1.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$5.16 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -125.65%
• Return on Assets: -95.19%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.70
• Quick Ratio: 4.70

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.45 per share
• Price / Book: 0.53

Miscellaneous

• Outstanding Shares: 3,652,000
• Free Float: 3,629,000
• Market Cap: $4.71 million
• Optionable: Not Optionable
• Beta: 1.95